Guidelines on the Labelling of Pharmaceutical Products

Version Aug 2021

Pharmacy and Poisons Board of Hong Kong
Contents

1. Introduction........................................................................................................................................3
2. General Labelling Requirements........................................................................................................3
3. Additional Labelling Requirements for Sterile Products.................................................................3
4. Additional Labelling Requirements for Certain Classes of Products..............................................3
5. Additional Labelling Requirements for Non-poisons and Part 2 Poisons.....................................4
6. Additional Labelling Requirements for Poisons............................................................................4
7. Additional Labelling Requirements for Biosimilar Products and Advanced Therapy Products.....5
8. Additional Safety Information Required for Certain Drugs...........................................................5
9. Points to Note....................................................................................................................................12
1. **Introduction**

1.1 These guidelines set out the labelling requirements in respect of pharmaceutical products for the purpose of registration. The requirements should not be treated as exhaustive. Other supplementary labelling may be required for particular products taking into consideration the nature and the intended uses of such products. In case of any doubt, the Pharmacy and Poisons Ordinance and Regulations, Cap.138 should be consulted.

2. **General Labelling Requirements**

2.1 Name of the product.
2.2 Name and quantity of each active ingredient.\(^a\).
2.3 Name and address of the manufacturer.
2.4 Hong Kong registration number of the product.
2.5 Batch Number.
2.6 Expiry date.
2.7 Product pack size and unit of quantity.
2.8 Storage condition (including specific storage condition, if any)\(^b\).

3. **Additional Labelling Requirements for Sterile Products**

3.1 Name of preservatives, if any.
3.2 Batch number and expiry date (on sales pack and on each ampoule/vial).

4. **Additional Labelling Requirements for Certain Classes of Products**

4.1 For embrocations, liniments, lotions, liquid antiseptics or other liquid medicines for external application –

“For external use only.  只供外用。”

4.2 For eye-drops –

---

\(^a\) Labelling of name of poison shall be in accordance with the Pharmacy and Poisons Regulations, Cap138A. For the accepted scientific name, please take reference to the International Nonproprietary Name (INN) recommended by the World Health Organization.

\(^b\) Storage condition should be supported by stability study. If applicable, the label should include specific storage condition e.g. do not freeze, special storage after reconstitutions/dilution/opening, etc. Terms such as “ambient conditions” or “room temperature” should be avoided.
"Not to be used one month after opening. 開蓋一個月後不可使用。”

4.3 For mouthwashes –
“Not to be swallowed. 不可吞服。”

4.4 For veterinary products (for veterinary products which contain Poisons, please refer to section 6.6) –
“For animal treatment only. 只限醫治禽畜用。”

5. Additional Labelling Requirements for Non-poisons and Part 2 Poisons

5.1 Dosage, route and frequency of administration in both English and Chinese.

6. Additional Labelling Requirements for Poisons

6.1 Medicines containing Part 1 Poisons (except for Schedule 3 Poisons) -
“Drug under Supervised Sales 監督售賣藥物”

6.2 Medicines containing Schedule 3 Poisons (e.g. P1 S1 S3 Poisons) -
“Prescription Drug 處方藥物”

6.3 Medicines containing Poisons except Schedule 1 and Schedule 3 Poisons made up ready for the internal treatment of human ailments\(d\) [other than medicines containing insulin and antihistamine as specified below] –
“Caution. It is dangerous to exceed the stated dose.”
「注意:服食過量有危險。」

6.4 Medicines containing insulin and made up ready for the internal treatment of human ailments\(d\) -
“Caution. It is dangerous to take this preparation except under medical supervision.”
「注意:非經醫生指示，服食此藥有危險。」

\(c\) Other in-use shelf life may be allowed on a case by case basis with justifications.

\(d\) As a general rule, medicines “made up ready for the internal treatment of human ailments” refer to such medicines of a package size of \textit{500 tablets/capsules or below} (for solid dosage forms), \textit{500 millilitres or below} (for liquid medicines) and medicines which are \textit{injectable products} regardless of package size.
6.5 Medicines containing an antihistamine [except Astemizole, Bilastine, Cetirizine, Desloratadine, Fexofenadine, Loratadine and Terfenadine] and made up ready for the internal treatment of human ailments -

“Caution. This may cause drowsiness. If affected, do not drive or operate machinery.”

「注意：此藥可使人昏昏欲睡，服後如有此情形，不得駕駛或動用機械。」

6.6 Medicines containing poisons made up ready for the treatment of animals -

“Poison. For animal treatment only.”

「毒藥：祇限醫治禽畜用。」

7. Additional Labelling Requirements for Biosimilar Products and Advanced Therapy Products

7.1 For biosimilar products -

Please refer to paragraph 6.1 to 6.3 of the <Guidance Notes on Registration of Biosimilar Products> for the additional labelling requirements.

7.2 For advanced therapy products -

(i) Product code

(ii) Unique donation identifier

(iii) If the product is for autologous use only

- Unique recipient identifier

- “For autologous use only” or the Chinese characters “只供自體使用”

The product code, unique donation identifier and unique recipient identifier must be assigned in accordance with the <Guidance on Labelling Requirements of Product Code, Unique Donation Identifier and Unique Recipient Identifier for Advanced Therapy Products>.

8. Additional Safety Information Required for Certain Drugs

8.1 Allopurinol

Safety warning on the label and/or package insert:
“Allopurinol should be discontinued at the first appearance of skin rash or other signs which may indicate an allergic reaction. In some instances, a skin rash may be followed by more severe reactions such as exfoliative, urticarial and purpuric lesions as well as Stevens-Johnson syndrome.”

8.2 **Angiotensin-Converting Enzyme Inhibitors (ACEI)**

Safety warning on the label:

“Caution. Contraindicated in pregnancy. 注意：孕婦忌食。”

8.3 **Aspirin**

Safety warnings on the label and/or package insert:

(i) “Keep out of reach of children. This medicine should not be given to children under 16 except on medical advice. 避免兒童誤取。非經醫生指示，十六歲以下兒童不可服用。”

(ii) “Consult your physician before taking aspirin during pregnancy or when nursing. 在懷孕或哺乳期的婦女，在服用阿司匹靈前需要徵詢醫生意見。”

(iii) “Aspirin irritates the stomach and can cause bleeding. It should not be taken by patients with stomach ulcers, persistent indigestion or liver disease. 阿司匹靈刺激胃部而可能引致出血，患有胃潰瘍、持續性消化不良或肝病的病人不可服用。”

8.4 **Astemizole**

Safety warning on the label and/or package insert relating to cardiovascular adverse events, drug interactions and rare reports of anaphylaxis reactions.

8.5 **Benzbromarone**

Safety warning on the label and/or package insert concerning the product’s potential to cause severe hepatic lesions:

“Caution: Severe hepatic lesions have been associated with the use of Benzbromarone. Patients who have hepatic disorders should avoid taking this product. 注意：服用苯溴馬隆(Benzbromarone)引致肝臟嚴重損傷。肝臟病患者應避免服用。”

Guidelines on the Labelling of Pharmaceutical Products
8.6 Benzocaine

Safety warnings for benzocaine for topical oral use on the label and/or package insert:

“Warnings: Methemoglobinemia

Use of this product may cause methemoglobinemia, a serious condition that must be treated promptly because it reduces the amount of oxygen carried in the blood. This can occur even if you have used this product before. Stop use and seek immediate medical attention if you or a child in your care develops: pale, gray or blue colored skin (cyanosis), headache, rapid heart rate, shortness of breath, dizziness or lightheadedness, fatigue or lack of energy.

Do not use for teething or in children under 2 years of age.

警告：正鐵血紅蛋白血症（methemoglobinemia）
使用本製品可能會導致正鐵血紅蛋白血症。這是一種必須及時治療的嚴重病症，因為它可以減少血液中的氧氣含量。即使你以前使用過本製品，也可能出現這種情況。如果你或你照顧的孩子有以下的症狀：蒼白、灰色或藍色皮膚（紫紺）、頭痛、心率加快、呼吸急促、頭暈或站立不穩、疲勞或缺乏氣力，請立即停用並盡快求醫。
本製品不可使用於出牙或2歲以下兒童。”

8.7 Chlorhexidine

Safety warning on the label and/or package insert:

“Warnings: Allergy Alert

This product may cause a severe allergic reaction. Symptoms may include: wheezing/difficulty breathing, shock, facial swelling, hives, rash. If an allergic reaction occurs, stop use and seek medical help right away.

警告：過敏警示
此製品可導致嚴重過敏反應。症狀包括：喘鳴/呼吸困難、休克、面部腫脹、蕁麻疹、皮疹。如果出現過敏反應，請立即停用並盡快求醫。”

8.8 Chlormezanone

Safety warning on the label and/or package insert:
“Severe cutaneous reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred infrequently. If skin reaction occurs, the drug should be stopped immediately.”

8.9 Codeine

Safety warnings on the label and/or package insert:

(i) Codeine is contraindicated for all children younger than 12 years of age.

(ii) Codeine should only be used to treat acute moderate pain in children above 12 years of age, and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen.

(iii) Codeine is contraindicated for post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy.

(iv) Avoid the use of codeine in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression.

(v) Codeine should not be used in people of any age who are known to be ultra-rapid metabolisers. Because of the potential for serious adverse reactions, including excess sedation, respiratory depression, and death in a breastfed infant, breastfeeding is not recommended during treatment with codeine.

Dosage instruction for cough medicines containing codeine:

The dosage instructions should be compatible with the following recommendations (given in respect of codeine phosphate):

Adults and children above 12 years: 15 - 30mg three or four times daily.

8.10 Fluoroquinolones

Safety warning for fluoroquinolones for systemic use on the label and/or package insert concerning the product’s potential to cause tendinitis or tendon rupture.
8.11 Lindane

Safety warning on the label and/or package insert:
“The product should only be used in patients who cannot tolerate, or have failed first-line treatment with safer medications. It must not be used on broken skin. It should not be used in infants, children under 6 years of age, pregnant women or nursing mothers, or the elderly with a history of seizure activity except on the advice of a physician. 此产品只應用於不能耐受較安全藥物或曾以較安全藥物作第一線治療但無效用的病人。切勿將此產品用於破損皮膚。除非醫生建議使用，否則此產品不應用於新生嬰兒、六歲以下兒童、懷孕或哺乳婦女，以及曾有痙攣發作的長者。”

8.12 Loratadine or Desloratadine

Safety warning on the label and/or package insert:
“Caution: Safe use of this product during pregnancy has not been established.”

8.13 Minoxidil

Safety warning for topical use Minoxidil for alopecia on the label and/or package insert to the effect that this product is not effective for all types of alopecia.

8.14 Miconazole

Safety warning for miconazole for oral or vaginal use on the label and/or package insert:
“Caution: Ask a doctor or pharmacist before use if you are taking the prescription blood thinning medicine warfarin, because bleeding or bruising may occur. 注意: 在服食抗凝血藥華法林期間使用本品可引致出血或瘀傷，請於使用前先向醫生或藥劑師諮詢意見。”

8.15 Oral Contraceptives

Safety warning on the label:
“Caution. While you are receiving this medication, you should see a doctor at least once a year for advice on suitability of continued use. 注意：你在服用此藥物期間，應至少每年一次向醫生請教是否適宜繼續服用。“

A package insert in both English and Chinese must also be made available in which information in dosage instructions and side effects should be included.
8.16 Phenylbutazone

Safety information in the package insert:

“Indications:  
- Active ankylosing spondylitis.
- Attacks of gout and pseudo-gout.
- Acute severe inflammation due to major surgery.

The following conditions, when no adequate response to other non-steroidal anti-inflammatory drugs:

- Acute exacerbations of rheumatoid arthritis and osteoarthritis.
- Acute states of non-articular rheumatic disease

Duration of treatment:  7 days; when a longer period of treatment is unavoidable, special precautions should be taken.

Age Limit:  Not for patients below 14 years of age.”

8.17 Phenylpropanolamine

The maximum daily dose should not exceed 100mg and on the label or package insert:

(i) “If you are under the care of your doctor or receiving continual prescribed medication or are pregnant then consult your doctor. 假如你是在醫生的照料下或長期服用藥物或懷孕, 請徵詢醫生意見。”

(ii) “Patients with high blood pressure, hyperthyroidism, heart disease or who are receiving monoamine oxidase inhibitors should not take the product. 患有高血壓、甲狀腺素高、心臟病或正接受單氨基酸抑制劑治療的病人不可服用此藥。”

(iii) “The product may aggravate conditions such as diabetes, glaucoma, or prostatic enlargement. 此藥可使糖尿病、青光眼和前列腺肥大等病症的病情轉壞。”

(iv) “The product should not be used as appetite suppressant. 此藥不可作食慾抑制劑使用。”

8.18 Salicylamide

Safety warning on the label and/or package insert:

“Keep out of reach of children. This medicine should not be given to children under 16 except on medical advice. 避免兒童誤取。非經醫生指示，十六歲以下兒童不可服用。”
8.19 Sulfonamides

Safety warning on the label and/or package insert:

“Fatalities associated with the administration of sulfonamides, although rare, have occurred due to severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.”

8.20 Terfenadine

Safety warning on the label and/or package insert relating to serious cardiovascular adverse events and drug interaction.

8.21 Tetracycline

The products of tetracycline for oral use should be labelled with the following safety warning:-

“To avoid dental disfigurement and discolouration, tetracycline should not be given to children under 12 years. 四環素會令牙齒損形變色，十二歲以下兒童不可服用。”

8.22 Ticlopidine

Safety warning on the label and/or package insert:

“This drug can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis and thrombotic thrombocytopenic purpura.”

8.23 Vitamin A

The products with vitamin A at a daily dose of 10,000 iu or above should be labelled with the following safety warning:-

“For the treatment of severe Vitamin A deficiency only. For pregnant women and children, medical advice should be sought before use. 只限醫治嚴重缺乏維他命 A 症狀。孕婦和兒童在服用前需先徵詢醫生意見。”

Remarks: The above is not an exhaustive list and other safety information may be required for individual products on a case-by-case basis.)
9. **Points to Note**

9.1 For Cold and cough (over the counter) products -
   The products should not have the dosage instructions on the sale pack label and/or the package insert for children under 6 years of age.

9.2 Undesirable Medical Advertisements Ordinance, Cap. 231 (UMAO) -
   Any labelling should not contravene the provisions of the **Undesirable Medical Advertisements Ordinance, Cap.231**.